Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) CEO Reshma Kewalramani sold 15,202 shares of the stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $497.00, for a total transaction of $7,555,394.00. Following the completion of the sale, the chief executive officer now owns 106,172 shares of the company’s stock, valued at approximately $52,767,484. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Reshma Kewalramani also recently made the following trade(s):
- On Friday, May 24th, Reshma Kewalramani sold 1,565 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $457.00, for a total transaction of $715,205.00.
Vertex Pharmaceuticals Stock Performance
NASDAQ VRTX traded up $0.48 during trading on Wednesday, reaching $490.80. The company’s stock had a trading volume of 950,201 shares, compared to its average volume of 1,208,669. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. The firm has a market cap of $126.65 billion, a price-to-earnings ratio of 31.82, a P/E/G ratio of 2.88 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $340.20 and a twelve month high of $498.77. The business’s fifty day moving average price is $471.08 and its 200-day moving average price is $435.99.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on VRTX shares. TD Cowen raised their price target on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company raised their price target on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. Canaccord Genuity Group restated a “sell” rating and set a $371.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Oppenheimer reaffirmed an “outperform” rating and set a $500.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. Finally, Evercore ISI raised shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a research report on Thursday, April 11th. Three analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $460.30.
Get Our Latest Stock Report on Vertex Pharmaceuticals
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. University of Texas Texas AM Investment Managment Co. purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $25,000. Arlington Trust Co LLC boosted its holdings in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 33 shares in the last quarter. Annapolis Financial Services LLC purchased a new stake in Vertex Pharmaceuticals during the first quarter worth about $27,000. ICA Group Wealth Management LLC purchased a new stake in Vertex Pharmaceuticals during the fourth quarter worth about $28,000. Finally, Baystate Wealth Management LLC boosted its holdings in Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 25 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read More
- Five stocks we like better than Vertex Pharmaceuticals
- Compound Interest and Why It Matters When Investing
- Food Processing Company Stock Gets Fried by Recall: Time to Buy
- The Role Economic Reports Play in a Successful Investment Strategy
- Entertainment Stock Offers A Rare and Tempting Entry Opportunity
- What is the NASDAQ Stock Exchange?
- Will China’s Interest Rate Cuts Ignite a Rally for This Stock?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.